SYK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Stryker Corp (SYK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and recent product innovations make it a compelling choice for long-term growth. Despite hedge fund selling, the stock's consistent growth and market leadership in medical technology outweigh short-term concerns.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 62.64, showing no overbought or oversold conditions. The stock is trading near resistance levels (R1: 372.791), with potential upside to R2: 379.057. Converging moving averages suggest stability in the trend.
Strong Q4 financial performance with 11.42% YoY revenue growth and 55.49% YoY net income growth.
Recent product launches, including the T2 Alpha Humerus Nailing System and Mako RPS, which enhance surgical efficiency and robotics capabilities.
Positive analyst sentiment, with multiple firms raising price targets and highlighting Stryker's growth potential.
Stock trend analysis predicts a 4.12% gain in the next month.
Hedge fund selling increased by 119.77% last quarter, indicating potential institutional profit-taking.
Gross margin slightly declined by -0.57% YoY in Q4 2025, though this is offset by strong revenue and net income growth.
Stryker delivered an impressive Q4 2025, with revenue increasing to $7.17 billion (up 11.42% YoY), net income rising to $849 million (up 55.49% YoY), and EPS growing to 2.2 (up 56.03% YoY). However, gross margin slightly declined to 62.54%, down -0.57% YoY.
Analysts are broadly positive on Stryker. Barclays raised its price target to $469, citing ample upside to fiscal 2026 growth. BTIG and Needham also raised targets, highlighting robust growth and strong product performance. While TD Cowen downgraded to Hold, the firm acknowledged Stryker's strengths but noted valuation concerns. Overall, the consensus remains bullish, with most firms maintaining Buy or Outperform ratings.
